Evaluation of non-small cell lung cancer by PET/CT with 64CuCl2: initial experience in humans

Human copper transporter 1 (hCtr1) is the main transporter of copper which has been involved as an essential cofactor in biological processes and mechanisms of action for cisplatin and its analogues. Although expression of hCtr1 is present in all tissues that require copper, several studies have sho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of nuclear medicine and molecular imaging 2020-01, Vol.10 (3), p.143-150
Hauptverfasser: García-Pérez, Francisco Osvaldo, Medina-Ornelas, Sevastian Salvador, Barron-Barron, Feliciano, Arrieta-Rodriguez, Oscar
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Human copper transporter 1 (hCtr1) is the main transporter of copper which has been involved as an essential cofactor in biological processes and mechanisms of action for cisplatin and its analogues. Although expression of hCtr1 is present in all tissues that require copper, several studies have showed that levels of expression are highly variable between normal and neoplastic tissues. We evaluated the potential diagnostic of the 64 CuCl 2 -PET/CT in patients with wild type non-small cell lung cancer (NSCLC). Eleven patients were included. Baseline 18 F-FDG-PET/CT and 64 CuCl 2 -PET/CT performed before to initiate treatment with platinum-based chemotherapy. 18 F-FDG-PET/CT detected a total of 68 lesions in different corporal sites: lung (24), regional lymph node (30), distant non-bone metastases (17) and bone metastases (14). Of total, 73% demonstrated high focal uptake of 64 CuCl 2 -PET/CT: 36% in primary tumor and 27% in lymph-nodes metastases. The detection-rates (DRs) was lower with 64 CuCl 2 PET/CT compared to 18 F-FDG-PET/CT, however, these was not statistically significant ( P = 0.108). A complete match was found in 2 patients. All patients were treated with platinum-based chemotherapy. According to RECIST 1.1 and PERCIST 1.0 criteria, most patients with highest uptake 64 CuCl 2 -PET/CT presented partial response (mean 3 cycles) corroborated with 18 F-FDG PET/CT. On the other hand, patients with very low uptake or faint uptake have progressive disease (3/16 patients). To our knowledge, this is the first study with 64 CuCl 2 -PET/CT in-human in patients with NSCLC chemo-naïve. Our results may represent that 64 CuCl 2 -PET/CT had a good ability for detect lesions. In addition, the 64 CuCl 2 uptake is based on the expression of Ctr1 transporters seeking to differentiate between those patients who may benefit from platinum-based therapy. More studies are necessary for confirm these findings.
ISSN:2160-8407
2160-8407